Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Vorolanib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EyePoint Pharmaceuticals to Highlight DURAVYU (Vorolanib) Clinical Progress
    EyePoint Pharmaceuticals to Highlight DURAVYU (Vorolanib) Clinical Progress

    26 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/26/2904464/0/en/EyePoint-Pharmaceuticals-to-Highlight-DURAVYU-vorolanib-intravitreal-insert-Clinical-and-Regulatory-Progress-and-Pipeline-Innovation-at-R-D-Day-2024.html

    GLOBENEWSWIRE
    26 Jun 2024
    Share Share
    EyePoint Shows Updated Positive Interim Data from Phase 1 Trial of EYP-1901
    EyePoint Shows Updated Positive Interim Data from Phase 1 Trial of EYP-1901

    12 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/eyepoint-pharmaceuticals-announces-updated-positive-interim-safety-and-efficacy-data-from-ongoing-phase-1-davio-clinical-trial-evaluating-eyp-1901-for-the-treatment-of-wet-amd-301481159.html

    PRNEWSWIRE
    12 Feb 2022
    Share Share
    EyePoint Reports +ve Interim Safety & Efficacy Data from EYP-1901 Phase 1 Trial
    EyePoint Reports +ve Interim Safety & Efficacy Data from EYP-1901 Phase 1 Trial

    14 Nov 2021

    // PIPELINEREVIEW

    https://pipelinereview.com/index.php/2021111479688/Small-Molecules/EyePoint-Pharmaceuticals-Reports-Positive-Interim-Safety-and-Efficacy-Data-from-Phase-1-DAVIO-Clinical-Trial-Evaluating-EYP-1901-for-the-Treatment-of-Wet-AMD.html

    PIPELINEREVIEW
    14 Nov 2021
    Share Share